JP2022551105A - アバプリチニブでの好酸球性障害の治療 - Google Patents
アバプリチニブでの好酸球性障害の治療 Download PDFInfo
- Publication number
- JP2022551105A JP2022551105A JP2022520638A JP2022520638A JP2022551105A JP 2022551105 A JP2022551105 A JP 2022551105A JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022520638 A JP2022520638 A JP 2022520638A JP 2022551105 A JP2022551105 A JP 2022551105A
- Authority
- JP
- Japan
- Prior art keywords
- eosinophilic
- compound
- pharmaceutically acceptable
- eosinophils
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025135336A JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962910931P | 2019-10-04 | 2019-10-04 | |
| US62/910,931 | 2019-10-04 | ||
| PCT/US2020/054221 WO2021067917A1 (en) | 2019-10-04 | 2020-10-05 | Treatment of eosinophilic disorders with avapritinib |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135336A Division JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022551105A true JP2022551105A (ja) | 2022-12-07 |
| JP2022551105A5 JP2022551105A5 (cg-RX-API-DMAC7.html) | 2023-10-13 |
Family
ID=73030210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022520638A Pending JP2022551105A (ja) | 2019-10-04 | 2020-10-05 | アバプリチニブでの好酸球性障害の治療 |
| JP2025135336A Pending JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025135336A Pending JP2025169361A (ja) | 2019-10-04 | 2025-08-15 | アバプリチニブでの好酸球性障害の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240075041A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4041244B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022551105A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114746096A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202126306A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021067917A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009515978A (ja) * | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Kit阻害剤に対する獲得耐性を伴う癌の治療 |
| JP2014521624A (ja) * | 2011-07-27 | 2014-08-28 | エービー サイエンス | 選択的プロテインキナーゼ阻害剤 |
| JP2015520186A (ja) * | 2012-06-07 | 2015-07-16 | デシフェラ ファーマシューティカルズ,エルエルシー | 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2593319T3 (es) * | 2005-05-02 | 2016-12-07 | Novartis Ag | Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico |
| ES2429107T3 (es) * | 2007-01-19 | 2013-11-13 | Bayer Healthcare Llc | Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT |
| EP2768480A1 (en) * | 2011-10-21 | 2014-08-27 | Rigel Pharmaceuticals, Inc. | Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine |
| MX365614B (es) * | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| CN109970745B (zh) * | 2018-04-16 | 2020-12-08 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡咯并三嗪类化合物及其药物组合物及其用途 |
-
2020
- 2020-10-05 CN CN202080081643.7A patent/CN114746096A/zh active Pending
- 2020-10-05 WO PCT/US2020/054221 patent/WO2021067917A1/en not_active Ceased
- 2020-10-05 TW TW109134501A patent/TW202126306A/zh unknown
- 2020-10-05 EP EP20797912.1A patent/EP4041244B1/en active Active
- 2020-10-05 JP JP2022520638A patent/JP2022551105A/ja active Pending
- 2020-10-05 US US17/766,200 patent/US20240075041A1/en active Pending
-
2025
- 2025-08-15 JP JP2025135336A patent/JP2025169361A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009515978A (ja) * | 2005-11-14 | 2009-04-16 | バイエル ヘルスケア エルエルシー | Kit阻害剤に対する獲得耐性を伴う癌の治療 |
| JP2014521624A (ja) * | 2011-07-27 | 2014-08-28 | エービー サイエンス | 選択的プロテインキナーゼ阻害剤 |
| JP2015520186A (ja) * | 2012-06-07 | 2015-07-16 | デシフェラ ファーマシューティカルズ,エルエルシー | 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物 |
Non-Patent Citations (5)
| Title |
|---|
| ANNALS OF TRANSLATIONAL MEDICINE, vol. 6(11), JPN7024004255, 2018, pages 232, ISSN: 0005434741 * |
| BLOOD, vol. 130 (Suppl_1), JPN7024004257, 7 December 2017 (2017-12-07), pages 2, ISSN: 0005434743 * |
| CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 10, JPN7024004256, 24 September 2015 (2015-09-24), pages 351 - 361, ISSN: 0005434742 * |
| SCIENCE TRANSLATIONAL MEDICINE, vol. Vol.9, eaao1690, JPN6024040812, 2017, pages 1 - 11, ISSN: 0005572012 * |
| THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 374, no. 26, JPN6024040811, 2016, pages 2530 - 2541, ISSN: 0005572011 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4041244B1 (en) | 2026-07-15 |
| EP4041244A1 (en) | 2022-08-17 |
| JP2025169361A (ja) | 2025-11-12 |
| TW202126306A (zh) | 2021-07-16 |
| WO2021067917A1 (en) | 2021-04-08 |
| US20240075041A1 (en) | 2024-03-07 |
| CN114746096A (zh) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4385571B1 (en) | A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis | |
| JP2017526713A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| US12257237B2 (en) | Tinostamustine for use in treating sarcoma | |
| US20200069703A1 (en) | Chemical entities that kill senescent cells for use in treating age-related disease | |
| JP2015511632A (ja) | メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与 | |
| JP2023058635A (ja) | 過活動膀胱の治療のためのビベグロンの投薬 | |
| US20240000789A1 (en) | Therapeutic combinations comprising a craf inhibitor | |
| KR20250099259A (ko) | 과민성 방광의 치료를 위한 비베그론의 용도 | |
| JP2025106456A (ja) | 胆管癌を治療するための方法 | |
| JP2025169361A (ja) | アバプリチニブでの好酸球性障害の治療 | |
| CN117982507A (zh) | 英菲格拉替尼在治疗胃癌和腺癌中的用途 | |
| JP2023501397A (ja) | 肥満細胞疾患および好酸球性障害の治療 | |
| CN112533600A (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| KR20150003786A (ko) | Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법 | |
| JP7762224B2 (ja) | 線維化症の予防または治療用薬学的組成物 | |
| KR20250145693A (ko) | 미토겐 활성화 단백질 키나제(mapk) 경로 변경을 이용한 고형 종양의 치료 방법 | |
| JP2026516050A (ja) | 多発性硬化症を治療するためのbtk阻害剤 | |
| CN117295498A (zh) | 用于预防或治疗纤维化的药物组合物 | |
| HK40096678A (en) | Pharmaceutical composition for preventing or treating fibrosis | |
| CN115120596A (zh) | 一种喹唑啉化合物及药物组合物的应用 | |
| CN115120732A (zh) | 一种喹唑啉化合物的药物组合物及其制备方法 | |
| HK40046131A (en) | Quinoline derivative used for treating small cell lung cancer | |
| JP2022547311A (ja) | 骨髄線維症の治療のためのmdm2阻害剤の使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231004 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231004 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240924 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241009 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241218 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250305 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250415 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20250410 |